Retchel Lazaro-Alcausi
A5033119985- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Colorectal Cancer Surgical Treatments
- Animal Virus Infections Studies
- COVID-19 and healthcare impacts
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
Royal Marsden NHS Foundation Trust
2019-2024
Royal Marsden Hospital
2019-2023
Assistance Publique – Hôpitaux de Paris
2019
Université Paris Cité
2019
Hôpital Beaujon
2019
Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies guide adjuvant treatment decisions. We are conducting the UK’s first multi-centre, prospective, randomised study determine whether de-escalation strategy using chemotherapy (ACT) decisions non-inferior standard of care (SOC) chemotherapy, measured by 3-year free...
Abstract Purpose: The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection. Experimental Design: TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal plasma collection ctDNA occurred pre-...
446 Background: ICONIC evaluated 4+4 cycles of FLOT-A (2-weekly standard FLOT with 10mg/kg the anti-PDL1 antibody avelumab) for perioperative treatment early-stage OGA. We report R0 resection rates, pathologic complete response rates (pCR), tumour regression grades (TRG) according to Mandard classification and progression free survival (PFS) data in modified intention treat population (mITT), translational analyses. Methods: is a single-arm phase II trial patients (pts) ≥cT2-4 or N+ The pCR...
Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity vaccines in patients GI receiving anti-cancer therapies is unclear. We conducted a prospective study to evaluate the prevalence neutralizing antibodies cohort cancer chemotherapy following vaccination.Between September 2020 April 2021, undergoing were enrolled. At baseline (day 0), days 28, 56, 84, we assessed serum spike (anti-S)...
201 Background: ICONIC is a single-arm phase II trial investigating the safety and efficacy of perioperative FLOT-A in resectable OGA. Following 3+3 design run-in phase, standard dose FLOT with 10mg/kg IV avelumab (dose level 0) q2weeks was taken forward into main study. The aims this pre-planned interim analysis were to assess R0 resection rates. Methods: occurred once 15th patient treated at 0 reached 30 days post-surgery. Results: At data cut-off, 15 patients had received least one cycle...
Abstract Background: The utility of molecular residual disease (MRD) detection by circulating tumor (ct)DNA in early-stage (pT2+ or N+, M0) esophagogastric adenocarcinoma treated with peri-operative systemic therapy has not been assessed prospective trials. Methods: This exploratory analysis the phase 2 ICONIC trial (NCT03399071), whether ctDNA can predict recurrence and determine efficacy 4xFLOT+avelumab (FLOT-A) before after surgery. Exome sequencing pre-treatment biopsies was successful...
<p>Venn diagrams of ctDNA detection by call method according to analysis population</p>
<p>Sensitivity analysis for landmark and longitudinal populations (n=33)</p>
<div>AbstractPurpose:<p>The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection.</p>Experimental Design:<p>TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal...
<p>TRACC B INVESTIGATORS</p>
<p>ctDNA detection rate at baseline and postoperative timepoints according to stage in the primary analysis population (n=143)</p>
<p>TRACC B INVESTIGATORS</p>
<p>Venn diagrams of ctDNA detection by call method according to analysis population</p>
<p>Bioinformatics review of patients with ctDNA detected no recurrence or death from CRC</p>
<p>Genotypic and epigenetic considerations</p>
<p>ctDNA detection rate at baseline and postoperative timepoints according to stage in the primary analysis population (n=143)</p>
<p>Bioinformatics review of patients with ctDNA detected no recurrence or death from CRC</p>
<div>AbstractPurpose:<p>The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection.</p>Experimental Design:<p>TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal...